



# An obligate cell-intrinsic function for CD28 in Tregs

Ruan Zhang,<sup>1</sup> Alexandria Huynh,<sup>1</sup> Gregory Whitcher,<sup>1</sup> JiHoon Chang,<sup>1</sup> Jonathan S. Maltzman,<sup>2</sup> and Laurence A. Turka<sup>1</sup>

<sup>1</sup>Transplant Institute, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.

<sup>2</sup>Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

**Tregs expressing the transcription factor FOXP3 are critical for immune homeostasis. The costimulatory molecule CD28 is required for optimal activation and function of naive T cells; however, its role in Treg function has been difficult to dissect, as CD28 is required for thymic Treg development, and blockade of CD28-ligand interactions has confounding effects in *trans* on nonregulatory cells. To address this question, we created Treg-specific *Cd28* conditional knockout mice. Despite the presence of normal numbers of FOXP3<sup>+</sup> cells, these animals accumulated large numbers of activated T cells, developed severe autoimmunity that primarily affected the skin and lungs, and failed to appropriately resolve induced experimental allergic encephalomyelitis. This *in vivo* functional impairment was accompanied by dampened expression of CTLA-4, PD-1, and CCR6. Disease occurrence was not due to subversion of *Cd28*-deficient Tregs into pathogenic cells, as complementation with normal Tregs prevented disease occurrence. Interestingly, in these “competitive” environments, *Cd28*-deficient Tregs exhibited a pronounced proliferative/survival disadvantage. These data demonstrate clear postmaturational roles for CD28 in FOXP3<sup>+</sup> Tregs and provide mechanisms which we believe to be novel to explain how interruption of CD28-ligand interactions may enhance immune responses independent of effects on thymic development or on other cell types.**

## Introduction

Tregs are a central element in the maintenance of self-tolerance. The transcription factor forkhead box p3 (FOXP3) is a key molecule mediating the development and function of natural Tregs (nTregs) (1–3). Patients with IPEX and *scurfy* mice, each of which lack functional FOXP3, have a severe systemic autoimmune syndrome characterized by a lack of functional Tregs and multiorgan disease (4, 5). Moreover, induced loss of FOXP3<sup>+</sup> T cells in healthy adult animals leads to rapid onset of catastrophic autoimmunity (6), further demonstrating the importance of FOXP3<sup>+</sup> Tregs in immune homeostasis.

CD28 is the prototypical and best-characterized costimulatory molecule on T cells (7, 8). CD28 signals are critical for optimal naive T cell activation, cytokine production, proliferation, and survival. Consistent with this, in rodent models of transplantation, transient blockade of the CD28 ligands CD80 and CD86 using CTLA4Ig leads to apoptosis of alloantigen-reactive cells, induction of Tregs, and long-term allograft survival (9, 10). However, perturbation of this system may have undesired immunostimulatory effects. CD28 is required for the intrathymic generation of nTregs. Thus, mice deficient in CD28 or its ligands have a dramatically reduced number of nTregs and develop accelerated autoimmunity on a NOD background (11). Moreover, there are also circumstances in which CTLA4Ig enhances immune responses. Blockade of CD28 engagement by CTLA4Ig leads to a rapid decrease of Tregs both in the thymus and in the periphery (11, 12) and, possibly as a direct result, breaks self-tolerance or


transplantation-tolerance in models in which Tregs play a major role in maintaining those states (13, 14).

The mechanisms for these effects remain incompletely defined. Previous studies addressing the role of CD28 in Tregs have used either *Cd28*<sup>-/-</sup> mice or blocking anti-B7 antibodies and/or CTLA4Ig. This body of work, while demonstrating the importance of CD28 in Tregs, has a number of limitations. First, as CD28 is required for intrathymic Treg development (11, 15), it is difficult to unravel the role of CD28 in Treg function and maintenance in these animals. Alternative approaches, such as the use of anti-B7 or CTLA4Ig, have the confounding variables of blocking both CD28 and CTLA-4 signals and doing so on all cells, not just Tregs. Thus, the experimental models may be confounded by the *trans* effects of loss of CD28-mediated costimulation and cytokine production by effector T cells or by interruption of CTLA-4 binding to CD80 and CD86, with the resultant loss of CTLA-4 mediated negative signals on effector T cells or CTLA-4-mediated suppression by Tregs (16, 17). Understanding the role of CD28 in Tregs is of particular clinical importance given the recent results of the phase III study of belatacept (an enhanced affinity variant of CTLA4Ig) showing higher rates, and more severe grades, of rejection (albeit with similar 1-year graft survival) in the belatacept-treated groups compared with a CNI-treated group (18).

To define the role of CD28 in the homeostasis and function of FOXP3<sup>+</sup> Tregs, we generated CD28-conditional knockout mice (*Cd28*-ΔTreg mice) that target CD28 in FOXP3<sup>+</sup> Tregs. We found that loss of CD28 in Tregs leads to two distinct and separable abnormalities — cell-intrinsic proliferation/survival defects, which manifest under competitive conditions, and functional impairment *in vivo*, which is accompanied by dampened expression of CTLA-4, PD-1, and CCR6. The net result is an autoimmune disease in *Cd28*-ΔTreg mice that is Treg intrinsic and prevented by complementation with CD28-sufficient Tregs. These data demon-

**Conflict of interest:** Laurence A. Turka has a family member employed by Novartis and an equity position in Novartis, and his family receives royalties from Myriad Genetics. Jonathan S. Maltzman has a family member employed by Morphotek and an equity position in GlaxoSmithKline.

**Citation for this article:** *J Clin Invest*. doi:10.1172/JCI65013.



**Figure 1** CD28 expression in control and *Cd28*- $\Delta$ Treg mice. **(A)** CD28 and YFP expression in gated CD4<sup>+</sup> lymph node cells. **(B)** CD28 expression in the indicated cells from thymus or lymph node. Analyses in **A** and **B** are from 6-week-old littermates and are representative of 3 independent experiments and litters.

strate clear postmaturational roles for CD28 in FOXP3<sup>+</sup> Tregs and provide what we believe to be a novel mechanism to explain how interruption of CD28/B7 signaling may enhance immune responses independent of effects on thymic development or on other cell types.

**Results**


*Generation and characterization of Cd28-ΔTreg mice.* We used BAC recombineering to introduce 2 loxP sites into the intronic sequences of the *Cd28* locus. Together, the inserted loxP sites flanked the extracellular (exon 2) and transmembrane (exon 3) domains of *Cd28* as well as some intervening intronic sequences (see Methods and Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI65013DS1). CD28-floxed mice were genotyped by PCR and Southern blotting (Supplemental Figure 1B), and we confirmed that insertion of the loxP sites did not interfere with the normal expression of the *Cd28* gene (Supplemental Figure 1C).

To generate mice with a specific deletion of CD28 in FOXP3<sup>+</sup> Tregs, *Cd28*<sup>fl/fl</sup> mice were bred with *Foxp3*<sup>YFP-Cre</sup> mice (19), and we refer to mice which carry the *Cd28*<sup>fl/fl</sup>*Cre*<sup>+</sup> genotype as *Cd28*- $\Delta$ Treg mice. Flow cytometric analysis revealed that CD28 was inactivated in peripheral CD4<sup>+</sup>YFP<sup>+</sup> Tregs from blood, lymph node, and spleen but not in YFP<sup>-</sup> “conventional” CD4<sup>+</sup> T cells or in CD8<sup>+</sup> T cells (Figure 1, A and B, and data not shown). As shown in Figure 1A, virtually all YFP<sup>+</sup> cells are CD28<sup>-</sup>, and, conversely, almost all

CD28<sup>-</sup> cells are YFP<sup>+</sup>, indicating the fidelity of *Cre* expression in these mice and the absence of significant leakiness. In the thymus, low levels of CD28 expression were observed on a portion of the YFP<sup>+</sup> cells in *Cd28*- $\Delta$ Treg mice (Figure 1B). Consistent with other mouse models that use *Foxp3*<sup>Cre</sup>, this is most likely due to the fact that these are newly generated Tregs in which the already translated CD28 protein has not been fully degraded.

The construct that we have used should delete sequences encoding exons 2 and 3, which encode the extracellular and transmembrane portions of the molecule, respectively, and the remaining portions of the gene are not expected to be transcribed or expressed. To confirm the absence of a residual truncated protein (which might have positive or negative signaling effects), we performed Western blotting using an antibody that binds to exon 4, which encodes an intracellular portion of CD28, and is not contained within the targeting region. We found a detectable specific band only in WT Tregs (Supplemental Figure 2). A nonspecific smaller band of approximately 40 kD was present in all samples and is not consistent with a truncated protein, since the undeleted exons (exon 1 and exon 4), even if translated, would lead to a protein predicted to be <10 kD. Thus, *Cd28*- $\Delta$ Treg mice effectively delete detectable CD28 protein in peripheral FOXP3<sup>+</sup> cells.

*Homeostasis of Tregs in Cd28-ΔTreg mice.* Analysis of young *Cd28*- $\Delta$ Treg mice revealed normal populations of APCs and NK and myeloid cells in thymi, spleens, lymph nodes, and bone marrow


**Figure 2**

Treg development and homeostasis in *Cd28*- $\Delta$ Treg mice. (A and B) Representative analysis for (A) CD4 and CD8 and (B) CD25 and YFP in the thymi (Thy), lymph nodes, and spleens (Spl) of littermate control (*Cd28<sup>+/+</sup> × Foxp3<sup>YFP-Cre</sup>*) and *Cd28*- $\Delta$ Treg mice (*Cd28<sup>fl/fl</sup> × Foxp3<sup>YFP-Cre</sup>*) mice (age 5 weeks). (C and D) Percentage of FOXP3<sup>+</sup> (defined as YFP<sup>+</sup>) in CD4<sup>+</sup>CD8<sup>-</sup> T cells from (C) thymi and (D) lymph nodes or spleens of 4- to 7-week-old mice. WT, control *Cd28<sup>+/+</sup> × Foxp3<sup>YFP-Cre</sup>* mice; cKO, *Cd28<sup>fl/fl</sup> × Foxp3<sup>YFP-Cre</sup>* mice. Symbols represent individual mice; horizontal bars indicate the mean.

(Supplemental Figure 3, A–C). Overall T and B cells were normal in all tissues except lymph nodes, in which a roughly 30%–50% increase in B cells was observed (Supplemental Figure 3A), with a reciprocal decrease in T cells (Figure 2A).

The proportions and total numbers of CD4/8 double-negative, double-positive, and single-positive cells were normal in the thymi of young *Cd28*- $\Delta$ Treg mice compared with those in littermate controls (Figure 2A and data not shown). However, there was a roughly 25%–30% decrease in the percentage of FOXP3<sup>+</sup> cells among the CD4 single-positive population in the thymi of *Cd28*- $\Delta$ Treg mice (Figure 2, B and C). Despite this, Treg percentages in lymph nodes and spleens of *Cd28*- $\Delta$ Treg mice were similar to those in littermate controls (Figure 2, B and D), and the level of CD25 expression on *Cd28*- $\Delta$ Tregs was comparable to that on WT Tregs in all lymphoid tissues examined (Figure 2B).

To further analyze Treg homeostasis, *Cd28*- $\Delta$ Treg mice and littermate controls were pulsed with BrdU for 3 days and sacrificed, and BrdU<sup>+</sup> Tregs were enumerated in lymphoid tissues. Consistent with the observation of reduced thymic Tregs in *Cd28*- $\Delta$ Treg mice, as shown in Figure 2, B and C, we observed decreased percentages of BrdU<sup>+</sup> Tregs within the thymi of these animals compared with control WT or male *Cd28<sup>fl/fl</sup> × Foxp3<sup>YFP-Cre</sup>* mice (Figure 3, A and B). In contrast, the percentage of lymph node and splenic Tregs that incorporated BrdU during the pulse period was similar in control and *Cd28*- $\Delta$ Treg mice (Figure 3, A and B, and data not shown). To exclude the confounding effects of newly generated Tregs from the thymus, which have been exported to the periphery, we thymectomized mice, pulsed them with BrdU 1 week later, and serially assayed peripheral blood T cells. We found similar rates of disappearance of BrdU<sup>+</sup> peripheral Tregs,




**Figure 3**

Treg homeostasis. (A and B) BrdU incorporation assay. 4- to 7-week-old WT or *Cd28-Δ*Treg mice were pulsed with BrdU every 12 hours for 3 days and sacrificed, and relevant tissues were analyzed by flow cytometry. Representative BrdU staining of gated CD4<sup>+</sup>FOXP3<sup>+</sup> cells is shown in A, and results of each experiment is plotted in B (Het, male *Cd28<sup>fl/fl</sup> × Foxp3<sup>YFP-Cre</sup>* mice; cKO, male *Cd28<sup>fl/fl</sup> × Foxp3<sup>YFP-Cre</sup>* mice). Symbols represent individual mice; horizontal bars indicate the mean. (C) BrdU incorporation in thymectomized mice, as per the protocol in A. CD4<sup>+</sup>FOXP3<sup>+</sup> cells from blood were analyzed at the indicated times after the last BrdU pulse. (D and E) Sorted WT Tregs or *Cd28-Δ*Tregs were labeled with CellTrace Violet and were stimulated by soluble CD3 plus mitomycin-treated T cell-depleted splenocytes (D) with or without rIL-2 or (E) with B7-1/B7-2 double-knockout T cell-depleted splenocytes.

regardless of whether they expressed CD28 (Figure 3C), which is in agreement with their indistinguishable steady-state levels (Figure 2, B and C). This rapid loss of detectable BrdU-positive cells is likely due to extensive cell division of Tregs, as has been previ-

ously seen (20). Collectively, these data suggest that, while thymic numbers of Tregs are reduced in *Cd28-Δ*Treg mice, once the cells are exported into the periphery, homeostasis, with respect to cell numbers and turnover, is preserved.




**Figure 4**

*Cd28*- $\Delta$ Treg mice develop autoimmunity with skin inflammation. (A) Gross appearance and lymph nodes and spleens from representative WT littermate control (labeled 1 and 3) and *Cd28*- $\Delta$ Treg (labeled 2 and 4) mice. (B) Cell numbers in lymph nodes and spleens from 2- to 5-month-old mice. 6 littermate pairs were analyzed. Data represent mean  $\pm$  SEM. (C) H&E staining of skin and lung tissue in a 3-month-old *Cd28*- $\Delta$ Treg mouse. Original magnification,  $\times 400$ . (D) CD44<sup>+</sup>CD62L<sup>hi</sup> cells in lymph nodes of a representative 4-month-old *Cd28*- $\Delta$ Treg mice. (E) Proportions of CD44<sup>+</sup> cells from lymph nodes of 2-month-old mice. 5 littermate pairs were analyzed. Data represent mean  $\pm$  SEM. (F) Percentage of IFN- $\gamma$ <sup>+</sup> cells in stimulated splenocytes from 2- to 5-month-old littermate pairs. Symbols represent individual mice; horizontal bars indicate the mean.

Last, we directly examined the ability of Tregs to proliferate in vitro. Although purified Tregs appear anergic in vitro, TCR, costimulation, and cytokines together can, under appropriate conditions, drive Treg proliferation (21). To examine the role of CD28 costimulation in Treg proliferation, we labeled sorted WT Tregs or *Cd28*- $\Delta$ Tregs with CellTrace Violet and stimulated them with anti-CD3 mAb in the presence of mitomycin-treated T cell-depleted splenocytes (Figure 3D). Under these conditions, in contrast to control Tregs, CD28-deficient Tregs proliferated minimally, although this could be “rescued” with exogenous IL-2. It is not currently known what cytokine(s) rIL-2 is “replacing,” as neither WT Tregs or *Cd28*- $\Delta$ Tregs produce IL-2 under these conditions (data not shown). Lack of cell division was not

due to cell death, as the viability of *Cd28*- $\Delta$ Tregs was comparable to that of control Tregs after the 3-day culture (data not shown). Further evidence for the role of CD28 costimulation of Tregs in supporting their proliferation is the fact that no proliferative differences were seen between Tregs from WT mice and those from *Cd28*- $\Delta$ Treg mice when B7-1/B7-2 double-knockout cells were used as APCs (Figure 3E).

*Depletion of CD28 in Tregs leads to autoimmune disease.* While appearing normal at birth and through 1 month of age, by 8 to 12 weeks of age 100% of *Cd28*- $\Delta$ Treg mice ( $n = 30$ ) developed signs suggestive of autoimmunity (Figure 4A). At onset, animals manifested crusting eyelids with facial hair loss, which progressed to hair loss on the trunk, skin lesions, and an ill appearance characterized




**Figure 5** Histologic analysis. (A and B) H&E staining of (A) livers, kidneys, and pancreata or (B) intestines and colons in 3-month-old  $Cd28-\Delta Treg$  mice. (C and D) Immunohistochemistry staining of skin tissues from a 3-month-old  $Cd28-\Delta Treg$  mice. Original magnification,  $\times 400$  (A and B);  $\times 100$  (C and D). Data are representative of at least 3 animals.

by ruffled fur, hunching, and reduced movements in the cage. This was associated with the development of lymphadenopathy and splenomegaly (Figure 4, A and B) and characterized by the accumulation of activated CD44<sup>+</sup> T cells (in both the CD4<sup>+</sup> and CD8<sup>+</sup> lineages) (Figure 4, D and E) and a high proportion of T cells primed for IFN- $\gamma$  production (Figure 4F). Consistent with the clinical picture of autoimmunity and the presence of high numbers of phenotypically activated T cells, histological analysis showed marked lymphocytic infiltration of skin and lung and scattered less intense foci of mononuclear cells in liver, pancreas, kidney, intestine, and colon (Figure 4C and Figure 5). Together, these data indicate that the absence of CD28 on Tregs leads to a slowly progressive systemic disease, with some features similar to those of *scurfy* mice, albeit developing with a slower tempo.

*Disease in Cd28-ΔTreg mice can be prevented by CD28-sufficient Tregs.* We considered that the disease observed in  $Cd28-\Delta Treg$  mice might be due to lack of normally functioning Tregs. An alternative possibility was that this was an act of commission, not merely omission; i.e., the CD28-deficient Tregs were becoming autoreactive effector cells that were initiating disease. This particularly seemed possible as Tregs are believed to be among the peripheral T cells with the highest affinity for self-antigens (22).

To examine this issue, we first cultured purified (>95% pure) CD28<sup>+</sup> or CD28<sup>-</sup> Tregs in vitro under proinflammatory conditions and then analyzed them for cytokine production following a brief restimulation. Following culture under Th1 conditions (Supplemental Figure 4A), 20%–25% of viable Tregs (both CD28<sup>+</sup> or CD28<sup>-</sup>) lost FOXP3 expression, and none of these






**Figure 6**

Analysis of female mice heterozygous for *Foxp3<sup>YFP-Cre</sup>*. (A–D) Flow cytometric analyses of thymus, lymph node, and spleen of a representative 3-month-old *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/+</sup>* female mouse and female littermate control. CD4<sup>+</sup> cells are gated in B (similar findings were observed in a CD8<sup>+</sup> gate; data not shown) and C, and CD4<sup>+</sup>FOXP3<sup>+</sup>CD25<sup>+</sup> cells are gated in D. (E) Percentage of YFP<sup>+</sup> *Cd28*-ΔTregs in a representative *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/+</sup>* female mouse and a *Cd28<sup>fl/+</sup>Foxp3<sup>YFP-Cre/+</sup>* female littermate control. In the former animal, depending on which X chromosome is randomly inactivated, some cells will delete CD28, and others will not. In these mice, YFP<sup>+</sup> Tregs are *Cd28<sup>-/-</sup>*, while YFP<sup>-</sup> Tregs are *Cd28<sup>+/-</sup>*. In the control, as the animals are heterozygous for the targeted CD28 allele but homozygous for *Foxp3<sup>YFP-Cre</sup>*, all Tregs in these mice will be *Cd28<sup>+/-</sup>*. In both cases, CD4<sup>+</sup>CD25<sup>+</sup>FOXP3<sup>+</sup> lymph node cells are shown. (F) *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/+</sup>* female mice were administered BrdU as in Figure 3, and BrdU staining of YFP<sup>+</sup> and YFP<sup>-</sup> cells was separately analyzed.

produced detectable IFN-γ. Of the cells that retained FOXP3 expression, equivalent percentages (~25%, i.e., ~15%–18% of the overall number of cells) of CD28<sup>+</sup> and CD28<sup>-</sup> Tregs produced IFN-γ. Under Th17 conditions (Supplemental Figure 4B) a

much higher proportion of cells lost FOXP3 expression (and the remaining ones were FOXP3<sup>dim</sup>) and produced IL-17 as well, but again, no appreciable difference was seen between CD28<sup>+</sup> and CD28<sup>-</sup> Tregs.



**Figure 7**

*Cd28-ΔTreg* development in bone marrow chimeras. B6 mice (CD45.2<sup>+</sup>Thy1.1<sup>+</sup>) were irradiated and reconstituted with a 1:1 ratio of bone marrow cells from WT B6 (CD45.1<sup>+</sup>Thy1.2<sup>+</sup>) and *Cd28-ΔTreg* mice (CD45.2<sup>+</sup>Thy1.2<sup>+</sup>). Blood cells were analyzed 6 months later, and CD4<sup>+</sup> cells were gated. Note that the WT mice did not carry the *Foxp3<sup>YFP-Cre</sup>* transgene. Thus, Tregs in the WT mice are CD25<sup>+</sup>YFP<sup>-</sup>, while in the *Cd28-ΔTreg* mice, they are CD25<sup>+</sup>YFP<sup>+</sup>. A total of 7 mice were analyzed with similar results.

To further discriminate whether disease in *Cd28-ΔTreg* mice was due to lack of functioning Tregs, we took advantage of the fact that, since *foxp3* is on the X chromosome, in female mice heterozygous for *Foxp3<sup>Cre</sup>* only approximately half of the Tregs should delete CD28 due to random inactivation of one X chromosome. In these mice, YFP<sup>+</sup> Tregs are *Cd28<sup>-/-</sup>* while YFP<sup>-</sup> Tregs are *Cd28<sup>+/+</sup>*. In the female *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/YFP-Cre</sup>* littermate control, as the animals are heterozygous for the targeted CD28 allele but homozygous for *Foxp3<sup>YFP-Cre</sup>*, all Tregs will be *Cd28<sup>+/+</sup>*.

Three-month-old female *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/+</sup>* mice (Cre-heterozygous mice) appeared healthy (data not shown). The thymic and peripheral lymphoid compartments had normal percentages of CD4 and CD8 cells, and lymph nodes and spleens were of normal size without an excessive number of CD44<sup>hi</sup> and/or CD62L<sup>lo</sup> cells (Figure 6, A and B, and data not shown). Interestingly, however, the percentage of Tregs was reduced in both the thymus and the periphery (Figure 6C), as WT Tregs did not undergo a compensatory expansion. Further analysis showed that CD28 was specifically deleted in YFP<sup>+</sup> (and not YFP<sup>-</sup>) Tregs and that the percentage of YFP<sup>+</sup> Tregs in the Cre-heterozygous mice was markedly below 50% (Figure 6, D and E), which we attribute to the loss of *Cd28-ΔTregs* in a competitive environment. Consistent with this, BrdU labeling revealed that the turnover rate of CD28-sufficient Tregs was approximately twice that of *Cd28-ΔTregs* (Figure 6F). To more specifically test this hypothesis, 1:1 mixtures of WT and *Cd28-ΔTreg* bone marrow were used to reconstitute heavily irradiated recipients. Six months after reconstitution, we found that while the two contributed equally to the overall hematopoietic compartment, virtually all Tregs were derived from WT bone marrow (Figure 7).

**Suppressive function of *Cd28-ΔTregs*.** These data, showing that a complement of normal Tregs is sufficient to prevent disease development in mice harboring CD28-deleted Tregs, suggested that disease was caused by a functional failure of *Cd28-ΔTregs*. Therefore, we next examined the ability of these cells to mediate regulatory responses. As shown in Figure 8A, *Cd28-ΔTregs* from young healthy mice inhibited the proliferation of naive T cells in an in vitro suppression assay as effectively as did control Tregs.


To examine the function of *Cd28-ΔTregs* in vivo, we used a standard adoptive transfer colitis model in *Rag1<sup>-/-</sup>* hosts, wherein mice received CD4<sup>+</sup>CD25<sup>-</sup>CD45RB<sup>hi</sup> cells from WT CD45.1 donors and Tregs (CD4<sup>+</sup>CD25<sup>hi</sup>) from either WT or *Cd28-ΔTreg* CD45.2 ani-

mals. Mice receiving *Cd28-ΔTreg* transfer alone remained healthy (Figure 8B). This is consistent with the data in Cre-heterozygous mice, where *Cd28-ΔTregs* did not induce disease, although that “assay” occurred in the presence of WT Tregs (Figure 6). These colitis data further demonstrate a lack of inherent pathogenicity in *Cd28-ΔTregs*. However, while *Cd28-ΔTregs* were not pathogenic, they failed to fully suppress colitis induced by naive T cells, though the weight loss of mice was slightly delayed compared with those receiving naive T cells alone (Figure 8B). Mice receiving naive T cells plus *Cd28-ΔTregs* had obvious histologic evidence of severe colitis with mononuclear cell infiltration through multiple layers of the bowel (Figure 8C). Consistent with these results, at the time of sacrifice, mice that received *Cd28-ΔTregs* had much higher percentages of effector cells and lower frequencies of FOXP3<sup>+</sup> cells in the colon (Figure 8, D and E) compared with mice receiving WT Tregs.

One of the disadvantages of the adoptive transfer colitis model is the potentially confounding issues of homeostatic expansion, cell homing, and cell survival (23). Indeed, part of the reason for the failure of *Cd28-ΔTregs* to suppress colitis may be their relative lack of homeostatic expansion in the immunodeficient environment of that model (Figure 8F). In order to examine the characteristics and function of *Cd28-ΔTregs* under more physiologic conditions, we first grafted BALB/c skin onto female *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/+</sup>* mice. We analyzed the percentage of CD28-sufficient and CD28-deleted Tregs present (in the same animals) in peripheral blood before transplant compared with the percentage 8 days after transplant (Figure 9, A and B). Blood was chosen to study, as it enabled us to sample the same animals before and after transplant. We found only a small increase in CD28-deficient Tregs in response to the skin transplant, while in contrast the percentage of CD28-sufficient Tregs doubled.


To study Treg function, we used an induced model of experimental allergic encephalomyelitis (EAE), in which disease resolution is Treg dependent (24). We observed equivalent kinetics, incidence, and disease score in WT and *Cd28-ΔTreg* mice (Figure 9C and data not shown). Strikingly, however, disease began to resolve within about 10 to 15 days after onset in WT mice, while it continued to progress in *Cd28-ΔTreg* mice, necessitating sacrifice of the animals (Figure 9C). Together, these two models show a requirement for CD28 expression on Tregs for expansion/accumulation of cells and for appropriate resolution of inflammation.





### Figure 8

Suppressive function of *Cd28-ΔTregs*. **(A)** In vitro suppression assay. Sorted WT naive cells were stimulated by soluble CD3 and T cell-depleted splenocytes with the addition of different ratios of WT Tregs or *Cd28-ΔTregs*. Tregs were sorted from 4-week-old mice. Teff, effector T cells. **(B)** In vivo colitis induction. Weight loss of *Rag1*<sup>-/-</sup> mice adoptively transferred with sorted CD4<sup>+</sup>CD45RB<sup>hi</sup> effector T cells with or without WT Tregs or *Cd28-ΔTregs*. A total of 6 mice were analyzed for each group. Data represent mean  $\pm$  SEM. **(C)** H&E staining of the colons of mice in **B**. Original magnification,  $\times 100$ . **(D and E)** Representative analysis of donor CD45.1<sup>+</sup>CD4<sup>+</sup> effector cells and regulatory cells in the colons of mice in **B**. **(F)** Sorted WT Tregs or *Cd28-ΔTregs* were labeled with CellTrace Violet and adoptively transferred to *Rag1*<sup>-/-</sup> hosts. Lymph node cells were analyzed 7 days after transfer. Data are representative of 3 experiments.



**Figure 9**

*Cd28-ΔTregs* have defective accumulation and function in vivo. **(A and B)** *Cd28<sup>fl/fl</sup>Foxp3<sup>Cre</sup>* female mice were transplanted with BALB/c body skin. WT and *Cd28-ΔTregs* from the blood were analyzed before or 8 days after transplantation. The percentage of increase of Tregs was analyzed in **B**, and each dot represents 1 mouse (horizontal bars indicate the mean). **(C)** Clinical scores of rMOG/CFA plus pertussis toxin-induced EAE in female WT *Cd28<sup>+/+</sup> × FOXP3<sup>YFP-Cre/YFP-Cre</sup>* (WT) or *Cd28<sup>fl/fl</sup> × FOXP3<sup>YFP-Cre/YFP-Cre</sup>* (*Cd28-ΔTreg*) mice. A total of 7 mice in each group are shown. Data represent mean ± SEM.

*Cd28-ΔTregs* have reduced expression of CTLA-4, PD-1, and CCR6. The data above indicated a defect in *Cd28-ΔTreg*-mediated suppression. Tregs may use multiple mechanisms to maintain immune surveillance in vivo. CTLA-4 has been shown to be important for Treg function (16, 17), and PD-1/PDL-1 interactions have been implicated as well (25, 26). We found a roughly 50% reduction of CTLA-4 and PD-1 expression in *Cd28-ΔTregs* (Figure 10, A and B). This was not a global reduction of Treg signature molecules, as the expression of FOXP3, CD25, and GITR was normal. Moreover, this was a cell-intrinsic process, as shown by examination of Tregs from female *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/+</sup>* mice, where comparison of YFP<sup>+</sup> (i.e., CD28-deficient) cells with YFP<sup>-</sup> (i.e., CD28-sufficient) cells within the same animals revealed defects in expression of CD25, CD44, CTLA-4, PD-1, GITR, and FOXP3 (Figure 10D). Tregs are known to upregulate CTLA-4, PD-1, and other activation markers upon stimulation (27–30). To determine how loss of CD28 affected this process we stimulated cells in vitro with anti-CD3 plus APCs for 3 days. As shown in Figure 10E, and consistent with the data for cells directly ex vivo (Figure 10, A and B), we observed prominent differences in upregulation of CD44 and PD-1 and, reproducible, but smaller differences in upregulation of CTLA-4, CD25, and CD69 in *Cd28-ΔTregs*.

As with conventional T cells, Tregs can circulate between peripheral and lymphoid tissues (28), and multiple chemokine receptors direct Treg migration (31, 32). As shown in Figure 10C, *Cd28-ΔTregs* directly ex vivo expressed reduced levels of CCR6, while other chemokine receptors, such as CCR4, CCR7, and CXCR4, were normal compared with WT Tregs. CCR6 is involved in the migration of Tregs to inflammatory tissues (33). The failure of upregulation of CCR6 in *Cd28-ΔTregs* is consistent with the observation of reduced FOXP3<sup>+</sup> cells in the skin of *Cd28-ΔTreg* mice (Figure 5). Collectively, these data suggest that defects in activation induced Treg markers and failure to migrate into inflammatory sites may contribute to the inability of these cells to adequately regulate immune responses in vivo.

## Discussion



Previous studies have yielded conflicting results as to whether or not CD28 signaling is required for Treg function. Tai et al. found that *Cd28<sup>-/-</sup> CD4<sup>+</sup>CD25<sup>+</sup>* thymocytes were unable to suppress in vitro; however, the requirement of CD28 for Treg development suggests that these were not a priori “imprinted” nTregs (15). Lyd-

dane and colleagues as well as Guo et al. reported that CD28 is required for iTreg generation but not function (34, 35). However, earlier work has not been able to address the issue of the role of CD28 in the function, maintenance, or survival of thymic-derived Tregs. To address this issue, we have created *Cd28-ΔTreg* mice in which CD28 is deleted under control of the FOXP3 promoter.

While Treg numbers are preserved in *Cd28-ΔTreg* mice, they nonetheless develop a systemic autoimmune process, most prominently affecting the liver and the skin. These inflammatory processes are reminiscent of the phenotype observed in *scurfy* mice (albeit less severe), consistent with a loss of suppressive functions in *Cd28-ΔTregs* and their failure to maintain immune surveillance in vivo. This is in contrast to their ability to suppress proliferative responses in an in vitro suppression assay. Such discordance between in vitro and in vivo functions of Tregs is being reported with increased frequency in various models and clearly reflects the complexity and multifaceted nature of the in vivo response.

The most striking abnormalities that we observed in *Cd28-ΔTregs* were marked decreases in CTLA-4, PD-1, and CCR6. CTLA-4 is upregulated by CD28 costimulatory engagement in non-Tregs (36) and also is required for Treg suppressive function (16, 17). PD-1 and PDL-1 signaling have been shown to regulate the development of induced Tregs (25) but have not been linked previously to alternations in Treg function. CCR6 recently was linked to the ability of Tregs to home to inflammatory sites, and thus decrease in expression of this molecule may be part of the spectrum of impaired regulation in *Cd28-ΔTreg* mice. In contrast to the severe lesions in the skin and lungs, other tissues, most notably the small intestine and colon, were generally spared in *Cd28-ΔTreg* mice. Whether or not this is a result of differential usage of homing receptors for Tregs in the gut is not yet known.

In addition to the in vivo functional defect in suppression in *Cd28-ΔTregs*, we observed a separable defect in homeostasis, which was only detected in a competitive or a lymphopenic environment. Thus, over time, in mixed bone marrow chimeras and female *Cd28<sup>fl/fl</sup>* mice heterozygous for *Foxp3<sup>Cre</sup>*, *Cd28-ΔTregs* almost disappeared and the Treg compartment was comprised almost completely of CD28-sufficient cells. Studies in the female heterozygotes indicated that this was accompanied by a defect in the homeostatic proliferation of *Cd28-ΔTregs*. It is likely, however, that *Cd28-ΔTregs* have a survival defect as well. When such cells were transferred alone, we noted a defect in lymphopenia-induced expansion (Figure 8F).



**Figure 10**

Cell surface markers in *Cd28-ΔTregs*. (**A–C**) Analysis of  $CD4^+CD25^+YFP^+$  cells from lymph nodes of 4-week-old *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre</sup>* male mice. Symbols represent individual mice; horizontal bars indicate the mean. (**D**) Comparison of WT and *Cd28-ΔTregs* in a representative female *Cd28<sup>fl/fl</sup>Foxp3<sup>YFP-Cre/+</sup>* mouse. Over 3 mice were analyzed. (**E**) Activation markers in sorted WT Tregs or *Cd28-ΔTregs* stimulated for 3 days with soluble CD3 plus mitomycin-treated T cell-depleted splenocytes. Experiments were repeated 3 times.





Moreover, in the adoptive transfer colitis studies, very few *Cd28*- $\Delta$ Tregs could be recovered from mice receiving these cells, either alone or with WT effectors, and it is likely that their defective survival in this latter model is a major contributor to failure of colitis prevention. It is interesting to note that colitis was not an observed pathologic feature of the autoimmune syndrome that the *Cd28*- $\Delta$ Treg animals developed. There are a number of potential explanations for this, including the effects of homeostatic expansion, alterations in cell migration, lack of new thymic Tregs being generated in the colitis model, differences in gut flora in between immunocompetent and immunodeficient animals, etc.

Interestingly, the only tissue in which we observed decreased numbers of Tregs was within the thymus. CD28 has a cell-intrinsic role in thymic Treg generation via its Lck-binding motif, and this function is independent of the ability of this motif to promote IL-2 production (15). As CD28 is not deleted until after FOXP3 is expressed, this result suggests an intrathymic role for CD28, either in the maintenance of FOXP3 expression or the proliferation/survival of thymic FOXP3<sup>+</sup> cells. The decrease in BrdU incorporation in Tregs lacking CD28 (or even those which are haplosufficient for CD28; Figure 3, A and B) argues for the latter possibility.

Recently, two groups found that a GFP-FOXP3 fusion protein, commonly used to track Tregs, was actually a hypomorph with altered molecular interactions and impaired downstream activation of the normal *Foxp3* gene expression/repression program (37, 38). In contrast, in the mice that we used, YFP-Cre is driven by an IRES, and thus the FOXP3 protein is intact and unaltered. Indeed, in female *Cd28*<sup>fl/+</sup>*Foxp3*<sup>YFP-Cre/+</sup> mice, we see similar percentages of YFP<sup>+</sup> (CD28<sup>-</sup>) and YFP<sup>-</sup> (CD28<sup>+</sup>) Tregs (2.84 ± 0.43 vs. 2.5 ± 0.54; *n* = 4), consistent with the fact that the *Foxp3*<sup>Cre</sup> genotype does not intrinsically impair Treg survival.

One potential concern regarding the use of *Foxp3*<sup>Cre</sup> as a means to target Tregs is the fact that FOXP3 may be transiently expressed by cells that are not truly committed to the Treg “lineage.” Recent studies have yielded conflicting results on the stability of FOXP3 expression and the question of whether or not there is a substantial population of ex-FOXP3 cells that have “diverted” into a Th lineage. We believe that this issue is unlikely to bear upon the interpretation of our data for at least two reasons. First, in mice CD28 is normally expressed in all T cells (39). In *Cd28*- $\Delta$ Treg mice, we did not detect a significant population of CD28<sup>-</sup>FOXP3<sup>-</sup> (i.e., CD28<sup>-</sup>YFP<sup>-</sup>) cells, suggesting that CD28 deletion is confined to cells that continue to express FOXP3. Given the role of CD28 in cell survival, it is likely that cells that are not Tregs, but transiently express FOXP3 and delete CD28, find themselves at a competitive disadvantage and are rapidly lost. Second, even if a population of “ex-FOXP3” effector/memory cells was present, they are extremely unlikely to account for the autoimmune pathology observed in *Cd28*- $\Delta$ Treg mice, as they would have been expected to cause disease in the mixed bone marrow chimeras and female Cre-heterozygous mice.

In summary, our data reveal distinct Treg-intrinsic roles for CD28 in both regulatory function and survival. These studies provide an additional mechanism whereby blockade of the ligands for CD28 and CTLA-4, namely CD80 and CD86, may in some circumstances enhance immune responses and contribute to acceleration of autoimmune processes or transplant rejection.

## Methods

**Gene targeting and generation of *Cd28*<sup>fl/fl</sup> mice.** A genomic *Cd28* fragment from BAC clone no. RP2478J76 (CHORI) and vectors PL253, PL451, and PL452

were used for preparation of a targeting vector to insert 2 LoxP sites, which would flank exon 2 and exon 3 of murine *Cd28* (Figure 1A). Detailed methodology of the recombineering protocol can be found at <http://ncifrederick.cancer.gov/research/brb/protocol.aspx>. Briefly, 1 LoxP sequence was inserted 150 bp upstream of exon 2, and the other LoxP sequence was placed downstream of exon 3 along with a neomycin selection cassette. An approximately 10-kb floxed *CD28* gene fragment was retrieved from the BAC and placed in a PL253 targeting vector. This construct was linearized and electroporated into the B6 ES cell line PB6, and G418-resistant colonies were selected. The 5' LoxP fragment introduced a new EcoRV site, and thus the floxed allele gave rise to a smaller 10-kb fragment (3' probe) or a 6-kb fragment (5' probe) as compared with the 14-kb fragment in the WT allele by Southern blot after EcoRV digestion (Figure 1B). We obtained 12 positive ES clones that were confirmed by Southern blotting. Three clones were injected into pseudopregnant female mice at the Penn Gene Targeting Core (University of Pennsylvania). Chimeric mice born from 2 ES clones exhibited germline transmission to their pups, which were intercrossed to produce *Cd28*<sup>fl/fl</sup> mice. These mice then bred with *Foxp3*<sup>YFP-Cre</sup> transgenic mice (a gift from A. Rudensky, Memorial Sloan-Kettering Cancer Center, New York, New York, USA) to generate mice with a deletion of CD28 specific to the T regulatory cell compartment. Mice were genotyped by PCR of tail DNA. Offspring that were found to express the *Foxp3*<sup>YFP-Cre</sup> transgene and were homozygous for the CD28-floxed allele (*Cd28*<sup>fl/fl</sup>) were used for analysis as homozygous mutant mice (*Cd28*- $\Delta$ Treg), while *Cd28*<sup>fl/+</sup>*Foxp3*<sup>YFP-Cre</sup> animals were used as littermate controls. All colonies were maintained under specific pathogen-free conditions at the animal facilities of Beth Israel Deaconess Medical Center. *Rag1*<sup>-/-</sup>, CD45.1<sup>+</sup>, and Thy1.1<sup>+</sup> B6 mice were purchased from The Jackson Laboratory, and B7-1/B7-2 double-knockout mice (B6 background) were a gift of Arlene Sharpe (Harvard Medical School).

**Western blotting.** T cells were lysed in ice-cold RIPA lysis buffer (Sigma-Aldrich) with protease and phosphatase inhibitors. Nuclei were removed by high-speed microcentrifugation in the cold, and samples were diluted 2:1 in 2× Laemmli sample buffer before gel loading. Anti-CD28 (c-20, Santa Cruz Biotechnology Inc.) was used to detect CD28 expression.

**Media, reagents, antibodies, and flow cytometry.** Cells were grown in RPMI 1640 (Mediatech Inc.) supplemented with 10% heat-inactivated FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, 2 mM L-glutamine, and 50 mM 2-mercaptoethanol (Sigma-Aldrich). Fluorescent anti-CD4, anti-CD25, anti-CD44, anti-CD62L, anti-CD8, anti-CD103, anti-CCR4, anti-CCR6, and anti-CCR7 antibodies were purchased from BioLegend. Anti-CTLA-4, anti-PD-1, anti-GITR, anti-CD127, anti-IFN, anti-CXCR3, and anti-CXCR4 were purchased from BD Biosciences – Pharmingen. The anti-FOXP3 Staining Kit was purchased from eBioscience. Murine recombinant IL-2 (rIL-2) was purchased from R&D Systems. BD Cytotfix/Perm buffer was used for intracellular staining. Cells were analyzed on a BD FACS-Calibur or a BD LSR II (BD).

**Naive and Treg isolation.** Spleen and lymph node cells were isolated from 4- to 8-week-old mice and enriched for CD4<sup>+</sup> cells with the mouse CD4<sup>+</sup> Enrichment Kit (Stemcell Technologies). Cells were stained with anti-CD25 PE, CD44-PerCP-cy5.5, CD62L-APC, and CD4-APC-cy7. CD4<sup>+</sup>CD25<sup>-</sup>YFP<sup>-</sup>CD44<sup>lo</sup>CD62L<sup>hi</sup> naive cells and CD4<sup>+</sup>CD25<sup>+</sup>YFP<sup>+</sup> Tregs were sorted by flow cytometry on a FACSARIA Cell Sorter (BD Biosciences). Cell purity was routinely greater than 95%. In an in vivo colitis model, CD45.1 B6 mice were used to sort CD4<sup>+</sup>CD25<sup>-</sup>CD45RB<sup>hi</sup> effector T cells.

**Cell activation and proliferation assays.** For total splenocyte stimulation, 1 × 10<sup>6</sup> splenocytes were stimulated by Leukocyte Activation Cocktail (BD Biosciences) for 6 hours and then fixed for cytokine staining.

For Treg proliferation assays, FACS-sorted CD4<sup>+</sup>CD25<sup>-</sup>YFP<sup>+</sup> cells were labeled with CellTrace Violet and cultured in complete medium in the pres-



ence of mitomycin-treated T cell–depleted splenocytes in 96-well plates at a density of  $10^5$  cells per well. For TCR stimulation, cells were cultured with soluble 0.5  $\mu\text{g}/\text{ml}$  anti-CD3 (2C11, BD) supplemented with or without 10 ng/ml rIL-2. Cell division was analyzed by CellTrace Violet dilution after 72 hours. For assessment of in vivo proliferation, CellTrace Violet–labeled Tregs were adoptively transferred to *Rag1*<sup>-/-</sup> mice by i.v. injection, and mice were sacrificed after 7 days. In all instances, cell viability was determined by flow cytometry using Live/Dead Fixable Aqua (Invitrogen).

**In vitro suppression assays.**  $1.5 \times 10^5$  CD4<sup>+</sup>CD25<sup>-</sup>CD44<sup>lo</sup>CD62L<sup>hi</sup> T cells were labeled by CellTrace Violet (Invitrogen) and cultured with  $4.5 \times 10^5$  irradiated T cell–depleted splenocytes plus 0.5  $\mu\text{g}/\text{ml}$  anti-CD3. The indicated ratios of CD4<sup>+</sup>CD25<sup>+</sup>YFP<sup>+</sup> cells from either WT or *Cd28*- $\Delta$ Treg mice were added to the cultures. CellTrace Violet profiles on YFP<sup>+</sup> cells were assessed by flow cytometry after 72 hours.

**T cell differentiation assays.** Sorted Tregs (CD4<sup>+</sup>YFP<sup>+</sup>) or naive T cells (CD4<sup>+</sup>YFP<sup>-</sup>CD44<sup>lo</sup>) were cultured in complete medium in the presence of mitomycin-treated T cell–depleted splenocytes in 96-well plates at a density of  $10^5$  cells per well. 1  $\mu\text{g}/\text{ml}$  soluble CD3 was added as the stimuli. For Th1 differentiation, mouse rIL-2 (10 ng/ml), IL-12 (5 ng/ml), and anti-IL-4 (10  $\mu\text{g}/\text{ml}$ ) were added. For Th17 differentiation, IL-1 (10 ng/ml), IL-6 (50 ng/ml), TGF- $\beta$ 1 (1 ng/ml), anti-IFN- $\gamma$  (10  $\mu\text{g}/\text{ml}$ ), and anti-IL-2 (10  $\mu\text{g}/\text{ml}$ ) were added into the culture. After 4 days of culture, cells were restimulated by PMA plus ionomycin with the presence of Golgi block for determination of cytokine production.

**In vivo BrdU labeling.** Mice were injected i.p. with 1 mg BrdU (BD Biosciences) every 12 hours for 3 days. Mice were sacrificed 12 hours after the final injection, and  $2 \times 10^6$  lymphocytes, splenocytes, or thymocytes were surface stained for CD4, CD8, CD25, and FOXP3. BrdU staining was performed using a BrdU Labeling Kit (BD Biosciences) per the manufacturer's instructions.

**Histology.** Tissues were harvested and fixed overnight at 4°C in 10% neutral buffered formalin. Following fixation, tissues were rinsed with cold PBS and embedded in paraffin. Tissues were sectioned (5  $\mu\text{m}$ ) and examined by H&E staining. For immunohistochemical analysis, skin sections were incubated with antibodies against mouse CD4, CD8, IL-17, IFN- $\gamma$ , and Gr-1 (BD Bioscience); CD25 and FOXP3 (BioLegend); and F4/80 (AbD Serotec), followed by biotinylated secondary antibodies (Vector). Sectioning and staining were performed by the histology core at Beth Israel Deaconess Medical Center.

**Bone marrow chimeras.** C57BL/6 Thy1.1 mice were irradiated (10 Gy) prior to reconstitution with  $4 \times 10^6$  total bone marrow cells from WT (CD45.1Thy1.2) and *Cd28*- $\Delta$ Treg (CD45.2Thy1.2) mice at 1:1 ratio. Five months later, peripheral blood mononuclear cells were analyzed flow cytometry.

**In vivo colitis model.** *Rag1*<sup>-/-</sup> mice were injected i.v. with  $6 \times 10^5$  CD4<sup>+</sup>CD25<sup>-</sup>CD45RB<sup>hi</sup> T cells, either alone or with  $2 \times 10^5$  WT (CD4<sup>+</sup>CD25<sup>+</sup>) Tregs or

*Cd28*- $\Delta$ Tregs (CD4<sup>+</sup>CD25<sup>+</sup>YFP<sup>+</sup>). Mice were weighed and examined every week for signs of disease and euthanized for tissue harvest at 8 to 10 weeks. Cells from lymph nodes, spleens, and colons were isolated and stained for CD4, CD25, and FOXP3. Colon tissues were fixed in 10% neutral buffered formalin (Fisher Scientific), cut into 5-mm sections, and stained with H&E.

**Skin transplantation.** Recipient mice were anesthetized with ketamine and xylazine, and a 1- $\times$  1-cm area of dermis was removed from the lateral trunk. A full-thickness donor skin graft was sutured to the exposed s.c. tissue bed using 4.0 chromic absorbable suture, and animals were bandaged after application of antibiotic ointment to the graft.

**EAE.** Animals were immunized s.c. in the abdominal flank with 200  $\mu\text{l}$  myelin oligodendrocyte glycoprotein peptide (MOG<sub>35-55</sub>) (UCLA Biopolymers Core) emulsified in complete Freund's adjuvant (Sigma-Aldrich), followed by i.p. injection of 200  $\mu\text{l}$  pertussis toxin (List Biological Laboratories) on days 0 and 2 after immunization. Immunized animals were monitored daily for weight loss and clinical disease score in a blinded manner. Disease was scored as follows: 0, no disease; 1, flaccid tail paralysis; 2, hind limb paresis; 3, bilateral hind limb paralysis; 4, hind and fore limb paralysis.

**Statistics.** Comparison of means between groups was done by using the 2-tailed Student's *t* test. Differences were considered statistically significant at  $P < 0.01$ .

**Study approval.** All experiments described in this manuscript were approved by the Institutional Animal Care and Use Committee at the Beth Israel Deaconess Medical Center or the University of Pennsylvania.

## Acknowledgments

We thank Terry Strom, Arlene Sharpe, Christophe Benoist, and members of the Turka, Strom, and Maltzman laboratories for many helpful discussions and Eva Csizmadia and Weihua Gong for technical assistance. This work was funded by NIH grants AI-037691 and AI-085160.

Received for publication May 25, 2012, and accepted in revised form November 1, 2012.

Address correspondence to: Laurence A. Turka, Transplantation Biology Research Center, Massachusetts General Hospital, MGH-East; Building 149-9019, 13th Street, Boston, Massachusetts 02129, USA. Phone: 617.724.7740; E-mail: lturka@partners.org.

Laurence A. Turka, Ruan Zhang, Alexandria Huynh, and JiHoon Chang's present address is: Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.

1. Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4(+)CD25(+) T regulatory cells. *Nat Immunol.* 2003;4(4):337–342.
2. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4(+)CD25(+) regulatory T cells. *Nat Immunol.* 2003;4(4):330–336.
3. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science.* 2003;299(5609):1057–1061.
4. Wildin RS, Smyk-Pearson S, Filipovich AH. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. *J Med Genet.* 2002;39(8):537–545.
5. Godfrey VL, Wilkinson JE, Russell LB. X-linked lymphoreticular disease in the scurfy (sf) mutant mouse. *Am J Pathol.* 1991;138(6):1379–1387.
6. Kim JM, Rasmussen JP, Rudensky AY. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. *Nat Immunol.* 2007;8(2):191–197.
7. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. *Immunology Today.* 1994;15(7):321–331.
8. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. *Immunol Rev.* 2011;241(1):180–205.
9. Wells AD, et al. Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. *Nat Med.* 1999;5(11):1303–1307.
10. Li XC, Strom TB, Turka LA, Wells AD. T cell death and transplantation tolerance. *Immunity.* 2001;14(4):407–416.
11. Salomon B, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. *Immunity.* 2000;12(4):431–440.
12. Tang Q, et al. Cutting edge: CD28 controls peripheral homeostasis of CD4(+)CD25(+) regulatory T cells. *J Immunol.* 2003;171(7):3348–3352.
13. Riella LV, et al. Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. *Am J Transplant.* 2012;12(4):846–855.
14. Lenschow DJ, et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. *Immunity.* 1996;5(3):285–293.
15. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. *Nat Immunol.* 2005;6(2):152–162.
16. Wing K, et al. CTLA-4 control over Foxp3+ regulatory T cell function. *Science.* 2008;322(5899):271–275.
17. Friedline RH, et al. CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. *J Exp Med.* 2009;206(2):421–434.
18. Vincenti F, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-



- group study in adult kidney transplant recipients. *Am J Transplant.* 2012;12(1):210–217.
19. Rubtsov YP, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. *Immunity.* 2008;28(4):546–558.
20. Fisson S, et al. Continuous activation of autoreactive CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells in the steady state. *J Exp Med.* 2003;198(5):737–746.
21. Masteller EL, Tang Q, Bluestone JA. Antigen-specific regulatory T cells—ex vivo expansion and therapeutic potential. *Semin Immunol.* 2006;18(2):103–110.
22. Jordan MS, et al. Thymic selection of CD4<sup>+</sup>CD25<sup>+</sup> regulatory T cells induced by an agonist self-peptide. *Nat Immunol.* 2001;2(4):301–306.
23. Barthlott T, Kassiotis G, Stockinger B. T cell regulation as a side effect of homeostasis and competition. *J Exp Med.* 2003;197(4):451–460.
24. McGeachy MJ, Stephens LA, Anderton SM. Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4<sup>+</sup>CD25<sup>+</sup> regulatory cells within the central nervous system. *J Immunol.* 2005;175(5):3025–3032.
25. Francisco LM, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. *J Exp Med.* 2009;206(13):3015–3029.
26. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. *Immunol Rev.* 2010;236:219–242.
27. Zhang N, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. *Immunity.* 2009;30(3):458–469.
28. Tomura M, et al. Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. *J Clin Invest.* 2010;120(3):883–893.
29. Gupta S, et al. Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3<sup>+</sup> Tregs. *J Clin Invest.* 2012;122(7):2395–2404.
30. Cheng G, Yuan X, Tsai MS, Podack ER, Yu A, Malek TR. IL-2 receptor signaling is essential for the development of Klrp1<sup>+</sup> terminally differentiated T regulatory cells. *J Immunol.* 2012;189(4):1780–1791.
31. Wei S, Kryczek I, Zou W. Regulatory T-cell compartmentalization and trafficking. *Blood.* 2006;108(2):426–431.
32. Siegmund K, et al. Migration matters: regulatory T-cell compartmentalization determines suppressive activity in vivo. *Blood.* 2005;106(9):3097–3104.
33. Yamazaki T, et al. CCR6 regulates the migration of inflammatory and regulatory T cells. *J Immunol.* 2008;181(12):8391–8401.
34. Lyddane C, Gajewska BU, Santos E, King PD, Furtado GC, Sadelain M. Cutting Edge: CD28 Controls dominant regulatory T cell activity during active immunization. *J Immunol.* 2006;176(6):3306–3310.
35. Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4<sup>+</sup>T cells. *J Immunol.* 2008;181(4):2285–2291.
36. Lindsten T, et al. Characterization of CTLA-4 structure and expression on human T cells. *J Immunol.* 1993;151(7):3489–3499.
37. Bettini ML, et al. Loss of epigenetic modification driven by the Foxp3 transcription factor leads to regulatory T cell insufficiency. *Immunity.* 2012;36(5):717–730.
38. Darce J, et al. An N-terminal mutation of the Foxp3 transcription factor alleviates arthritis but exacerbates diabetes. *Immunity.* 2012;36(5):731–741.
39. Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. *J Immunol.* 1992;149(2):380–388.